A narrative synthesis of research with 5-MeO-DMT

Plant- and fungi-derived classical psychedelics have long histories of ritual and therapeutic use, and in recent decades clinical research into compounds such as psilocybin and LSD has resumed after earlier regulatory restrictions. A recurrent practical issue is that classical psychedelics vary substantially in duration of action: LSD can last about 12 hours after oral ingestion, psilocybin about 6 hours, while shorter-acting substances may offer logistical and cost advantages for therapeutic delivery. Earlier observational literature and survey studies have suggested potential therapeutic benefits from short-acting tryptamines, but controlled human data are sparse. This narrative review set out to synthesise the available preclinical, epidemiological and human-use literature on 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) to inform clinical development. The authors aimed to collate evidence on chemistry, pharmacology, metabolism, safety and reported beneficial and adverse effects, with an explicit view to identifying knowledge gaps relevant to initiating controlled clinical trials of 5-MeO-DMT in humans.

Ermakova and colleagues identified references by searching PubMed from January 1965 to October 2020 using terms for 5-methoxy-N,N-dimethyltryptamine and chemical variants; the precise search strings are reported in the paper's supplementary material. The search was supplemented by hand-searching bibliographies and cross-checking earlier reviews. Papers in English, Russian and Spanish were eligible, reflecting the authors' language proficiencies. Selection focused on studies providing novel information about 5-MeO-DMT relevant to clinical research; studies solely on chemical synthesis, forensic detection, or mere identification of 5-MeO-DMT in plants were excluded. The authors synthesised findings using a narrative approach rather than formal meta-analysis. The extracted text notes that numbers of screened and included/excluded sources are presented in a figure, but those counts are not reproduced in the extracted material provided here.

History, occurrence and traditional use: 5-MeO-DMT was first synthesised in 1936 and isolated from Dictyoloma incanescens in 1959. It occurs in numerous plant genera (for example Anadenanthera, Phalaris, Virola), in some fungi (Amanita spp.), in glandular secretions of the Sonoran Desert toad Incilius alvarius, and has been reported in mammals. Evidence that 5-MeO-DMT is endogenously present in humans is mixed: pooled detection rates across older and newer studies were 2/113 in urine, 20/39 in blood and 40/136 in cerebrospinal fluid, but only the later studies used mass spectrometry and methodological heterogeneity limits firm conclusions. Indigenous peoples of South America have used 5-MeO-DMT-containing plants in snuffs for ritual purposes; use of toad secretions appears more recent and is not conclusively documented historically. Legal status and prevalence: 5-MeO-DMT is legally controlled in several countries (for example the USA, UK, Australia, New Zealand) but remains uncontrolled in others, including Canada, and is not listed under the UN Convention on Psychotropic Substances. Epidemiological data suggest use is rare: in the US National Survey on Drug Use and Health from 2002–2019 (n = 722,653 respondents) 33 and 13 respondents reported lifetime use of 5-MeO-DMT or bufotenine/toad secretions respectively (unweighted estimates 0.0046% and 0.0018%); a rough prevalence estimate is around 0.003%. Chemistry and in vitro pharmacology: Chemically, 5-MeO-DMT is a tertiary tryptamine (C13H18N2O, molecular weight 218.298 g/mol). In vitro binding and functional data indicate it is a non-selective serotonin (5-HT) receptor agonist with relatively high affinity at several 5-HT receptor subtypes. Radioligand data report about 300-fold selectivity for 5-HT1A (Ki ≈ 3 nM) versus 5-HT2A (Ki ≈ 907 nM). Functional assays show complex, pathway-selective signalling: for example, 5-MeO-DMT preferentially activates PLA2 over PLC signalling and demonstrates marked differences in G-protein versus β-arrestin pathway potency. The authors note discrepancies across binding studies for some receptor classes and call for further work to resolve the full receptor profile. Pharmacokinetics and metabolism (preclinical): In rodents, 5-MeO-DMT has rapid absorption with plasma Cmax reached in about 5–10 minutes and short terminal half-lives (mice t1/2 12–19 min; rats t1/2 6–16 min). The molecule is lipid-soluble, crosses the blood–brain barrier, and distributes to cortex, thalamus, hippocampus and other brain regions. Metabolism is dominated by MAO-A-mediated oxidative deamination; O-demethylation, N-demethylation and N-oxygenation play smaller roles. In rats the main urinary metabolite is 5-methoxyindoleacetic acid (5-MIAA, 54%), followed by 5-hydroxy-N,N-dimethyltryptamine glucuronide (23%), 5-HIAA (14%) and bufotenine (9%). Pharmacokinetics become non-linear at higher doses in mice, consistent with MAO-A saturation; reported pharmacokinetic parameters for mice included Vmax 2.76 mmol/min per kg, Km 13.2 mM, clearance 0.21 min^-1 kg^-1 and an additional CYP2D6-dependent clearance of 0.0256 L/min per kg. In vivo pharmacology and behavioural effects: Animal studies across many species and routes show behavioural effects that include reductions in locomotion and investigatory activity, forepaw treading, flat-body posture, Straub tail and hindlimb abduction. Drug discrimination studies indicate both 5-HT1A and 5-HT2A components, with 5-HT1A playing a major role. The head-twitch response—a 5-HT2A-mediated signature of classic hallucinogens in rodents—is induced by 5-MeO-DMT and is attenuated by selective 5-HT2A antagonists and absent in 5-HT2A knockout mice. Dose ranges and effects are non-linear and vary by species; the authors warn that direct mg/kg cross-species comparisons are not appropriate without scaling. Neurobiological effects: Preclinical electrophysiology and imaging work suggests 5-MeO-DMT alters medial prefrontal cortex oscillatory activity and cortico-thalamic coherence, disrupts low-frequency mPFC oscillations and decreases BOLD responses in visual cortex and mPFC. Some effects were reversed by 5-HT1A antagonists, highlighting the role of 5-HT1A receptors. In mice, a single dose promoted hippocampal neuronal progenitor proliferation and maturation. Human field EEG data (one report) after smoked 5-MeO-DMT showed acute alpha suppression followed by an alpha rebound and increased delta/theta power correlating with subjective intensity. Physiological effects, toxicology and tolerance: Cardiovascular responses are variable and may include transient biphasic or triphasic blood pressure changes, modest heart rate effects and bradycardia in some primate studies. Thermoregulatory effects are dose-dependent and non-linear; 5-HT1A versus 5-HT2A actions can produce opposing hypo- versus hyperthermic effects. Analgesic and nociceptive responses are also non-linear. Endocrine effects include dose-dependent prolactin increases in rodents and transient salivary cortisol elevation following inhalation in humans. Immunomodulatory effects were reported in vitro and in organoid proteomics, including reduced proinflammatory cytokines and increased IL-10 mediated via σ-1 receptors. Reported LD50 values vary by species (sheep 1 mg/kg; mice 48–278 mg/kg depending on route; cats 15 mg/kg). Tolerance to some effects develops with frequent administration in animals; no physical dependence or withdrawal signs were reported. Drug interactions: Co-administration with MAO-A inhibitors (for example harmaline) in mice markedly inhibited MAO-A metabolism, increased conversion to bufotenine and prolonged exposure, with associated toxicity; chronic MAOI treatment, conversely, suppressed acute responses. Other interactions in rodents included potentiation or attenuation of various behaviours with agents such as lithium, benzodiazepines, tricyclic antidepressants and SSRIs, with both acute and chronic treatment effects described. Human use, epidemiology and outcomes: No controlled human clinical trials of 5-MeO-DMT were identified. Published human data comprise case reports, retrospective surveys and small prospective field studies. Self-report surveys indicate motivations were predominantly spiritual exploration (68%), recreation (18%) or healing (14%); most users reported trying 5-MeO-DMT fewer than four times. Survey respondents commonly described intense transcendent experiences often marked by ego-dissolution and non-dual awareness, frequently without visual imagery. In one pooled survey 90% reported positive experiences, 57% met criteria for a complete mystical experience on the MEQ-30, and approximately 37% reported challenging experiences. In a sample of 362 people who used 5-MeO-DMT in group settings, of those reporting a diagnosis of depression (41%) or anxiety (48%), 80% and 79% respectively reported improvement after use; greater intensity of mystical experience correlated with reported improvements. Two small prospective studies (vapourised 5-MeO-DMT and toad secretions, n reported as 42 in one) found increases in mindfulness measures and reductions in depression and anxiety scores immediately post-session that persisted at follow-up. Adverse events, fatalities and safety signals: Acute adverse effects described in surveys and case reports include intense fear, anxiety, confusion, panic, nausea, vomiting, transient headache, chest or abdominal pressure, shaking and dissociative memory loss. Delayed effects reported up to one week included muscle tension, sleep difficulties and re-experiencing or 'flashbacks'; rare cases of psychosis have been reported. Toxicity and deaths in published reports typically involved 5-MeO-DMT taken with other substances, notably MAOIs or other drugs of abuse. Individual severe cases included a 5-year-old child with seizures after licking toad secretions and a 17-year-old with rhabdomyolysis after combined 5-MeO-DMT and harmaline; a fatality following ayahuasca with 5-MeO-DMT has also been reported. National databases cited in the paper did not list deaths directly attributable to 5-MeO-DMT, but the authors note limitations in routine testing and reporting.

The authors conclude that 5-MeO-DMT is a short-acting serotonergic tryptamine with a distinct subjective profile—often intense ego-dissolution and mystical-type experiences, commonly without prominent visual phenomena—and that the compound warrants further controlled human investigation. Preclinical data show non-linear and sometimes biphasic effects across pharmacokinetic, thermoregulatory, nociceptive and cardiovascular domains, and the metabolism is dominated by MAO-A with a CYP2D6-dependent pathway producing bufotenine. These pharmacological features imply the need for careful dose-finding and pharmacokinetic characterisation in humans, as well as consideration of individual metabolic genotypes. Ermakova and colleagues recommend applying established safety procedures used in psychedelic research to 5-MeO-DMT trials, including screening, monitoring and exclusion of concomitant MAO inhibitors and lithium because of interaction risks. The authors note reports of flashbacks and discuss hallucinogen-persisting perception disorder (HPPD) as a rare but poorly defined syndrome; they highlight complicating factors such as polysubstance use and pre-existing vulnerabilities. While survey data suggest rapid anxiolytic and antidepressant effects analogous to those reported for other psychedelics and ketamine, the authors emphasise that therapeutic potential remains hypothetical and that robust clinical trials are required. Limitations acknowledged by the authors include the absence of published controlled human laboratory studies, reliance on heterogeneous animal models and retrospective self-report surveys that are subject to selection and recall biases. They also point to methodological gaps in receptor-binding data and inconsistent detection of endogenous 5-MeO-DMT in human samples. As next steps the authors advocate for healthy volunteer trials to establish human pharmacokinetics, safety and appropriate dosing regimens before proceeding to clinical efficacy studies.

5-MeO-DMT is a short-lasting psychedelic with a distinctive subjective effect profile and a preclinical pharmacology broadly similar to classic serotonergic psychedelics. The balance of available evidence suggests a risk profile comparable to other classic psychedelics, but important gaps remain—most notably the lack of controlled human pharmacokinetic and safety data. Given reported high rates of ego-dissolution and mystical-type experiences, which have been associated with therapeutic benefit in other psychedelic research, the authors conclude that controlled clinical exploration of 5-MeO-DMT is warranted using established psychedelic research safety precautions.